Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | CPA1 | P15085 | 2/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | FPR2 | P25090 | 5/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1498340 | 1.00 | MME (0.59) | MMENPSR1MEN1KMT2ANAALAD2 | |
| SCHEMBL7354845 | 0.90 | CAPN1 (0.55) | — | |
| SCHEMBL7354848 | 0.90 | CAPN1 (0.55) | — | |
| Piperidine SCHEMBL1528563 | 0.87 | L3MBTL1 (0.48) | MMENPSR1MEN1KMT2ANAALAD2 | |
| SCHEMBL5964935 | 0.87 | FOLH1 (0.58) | MMENAALAD2ACECPA1ACE2 | |
| SCHEMBL6377128 | 0.87 | FOLH1 (0.58) | MMENAALAD2ACECPA1ACE2 | |
| SCHEMBL1012022 | 0.86 | MME (0.63) | MMENPSR1NAALAD2L3MBTL1ACE | |
| SCHEMBL1012023 | 0.86 | MME (0.63) | MMENPSR1NAALAD2L3MBTL1ACE | |
| SCHEMBL1012053 | 0.86 | MME (0.63) | MMENPSR1NAALAD2L3MBTL1ACE | |
| SCHEMBL21791304 | 0.85 | MME (0.58) | MMENPSR1MEN1KMT2ANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255263-B2 | Antithrombotic compounds | KING'S COLLEGE LONDON (GB) | 2016-02-09 | — | — | US | claimed |
| US-20120232014-A1 | ANTITHROMBOTIC COMPOUNDS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-09-13 | — | — | US | claimed |
| EP-2473181-A1 | ANTITHROMBOTIC COMPOUNDS | King's College London (GB) | 2012-07-11 | — | — | EP | claimed |
| WO-2011027175-A1 | ANTITHROMBOTIC COMPOUNDS | KING'S COLLEGE LONDON (GB) | 2011-03-10 | — | — | WO | claimed |
| US-20100287636-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INDUCIBLE T CELL KINASE (ITK) AND TREATING ASTHMA AND BRONCHIAL INFLAMMATIONS | San Diego State University Foundation, dba San Diego State University Research Foundation (US) | 2010-11-11 | — | — | US | claimed |
| EP-1489968-B1 | ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2008144351-A2 | COMPOSITIONS AND METHODS FOR INHIBITING INDUCIBLE T CELL KINASE (ITK) AND TREATING ASTHMA AND BRONCHIAL INFLAMMATIONS | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-11-27 | — | — | WO | claimed |
| US-6287794-B1 | Factor Vlla inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-11 | — | — | US | claimed |
| WO-2001027138-A2 | MODULATORS OF SREBP PROCESSING | TULARIK INC. (US) | 2001-04-19 | — | — | WO | claimed |
| JP-6025291-A | — | — | None | — | — | JP | disclosed |
| JP-5155898-A | — | — | None | — | — | JP | disclosed |
| CN-113811278-B | Concealment of hypomineralized lesions | 墨尔本大学 | 2024-12-31 | — | — | CN | disclosed |
| US-11981753-B2 | Peptide compound and application thereof, and composition containing peptide compound | SHANGPHARMA INNOVATION INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-11807660-B2 | Peptide compound and application thereof, and composition containing peptide compound | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2023-11-07 | — | — | US | disclosed |
| EP-0508220-A1 | Derivatives of amindinophenylalanine, procedure for their preparation, their utilisation and compositions comprising them | BEHRINGWERKE Aktiengesellschaft (DE) | 1992-10-14 | — | — | EP | disclosed |
| WO-1992007869-A1 | INHIBITORS AND SUBSTRATES OF THROMBIN | THROMBOSIS RESEARCH INSTITUTE (GB) | 1992-05-14 | — | — | WO | disclosed |
| US-4977168-A | Derivatives of the N α-arylsulphonylaminoacyl-p-amidinophenyl-alaninamides, and their use as medicaments | SANOFI (FR) | 1990-12-11 | — | — | US | disclosed |
| EP-0236164-B1 | DERIVATIVES OF N-ALPHA-ARYLSOLFONYLAMINOACYL P-AMIDINO-PHENYLALANINAMIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THEIR INTERMEDIATES | SANOFI (FR) | 1990-09-12 | — | — | EP | disclosed |
| US-4791102-A | ANTICOAGULANTS | SANOFI (FR) | 1988-12-13 | — | — | US | disclosed |
| EP-0236164-A1 | Derivatives of N-alpha-arylsolfonylaminoacyl p-amidino-phenylalaninamides, process for their preparation, their use as medicaments and their intermediates | SANOFI (FR) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981753-B2 | Peptide compound and application thereof, and composition containing peptide compound | KISS1R, NPY1R, GLP1R | MME 289/4885NPSR1 65/4885MEN1 135/4885 |
| US-11807660-B2 | Peptide compound and application thereof, and composition containing peptide compound | KISS1R, VIP, SSTR3 | MME 245/4885NPSR1 71/4885MEN1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.